

**RfP Publication Reference:** 021-6081/20  
**File Referene:** CPSU 164119N20JP

Date: Tuesday, 25 August 2020

For the attention of all interested Economic Operators

**Request for Participation (Negotiation) for the Supply of Mycophenolate Sodium  
(Myfortic) 360mg Tablets**

**Clarifications No. 1**

Reference is made to the Request for participation in caption.

Hereunder please find a clarification which is construed to form an integral part of the RfP procurement document.

**Clarification 1:**

Further to RFP 021-6081/20 CPSU 164.119.N.20.JP, the product specifications state “Mycophenolate 360mg EC tablets (Myfortic®)”.

Kindly clarify whether Mycophenolate Sodium 360mg Enteric Coated Tablets with equivalent bioavailability is acceptable.

**Answer 1:**

The EMTC has approved the branded product as a continuation of treatment for patients who were on the branded Myfortic and hence DPA proceeded with the branded specifications.

*All other tender documents, conditions and requirements, which are not superseded by this Clarification, remain in place.*